A Discussion on the "Right To Try" Bill
President Trump signed the ‘Right To Try’ drug bill last week, allowing terminally ill patients access to experimental medical treatments not yet approved by the Food and Drug Administration. We discuss the key features of the bill and also have a conversation with a proponent and opponent of it.
- Dr. Jeffrey A. Singer, Senior Fellow at the Cato Institute and works in the Center for the Study of Science and the Department of Health Policy Studies
- Starlee Coleman, Senior Policy Advisor, The Goldwater Institute, free-market public policy research and litigation organization
- Dr. Robert I. Field, Healthcare Freelance Editor, Professor at Drexel University Kline School of Law & Dornsife School of Public Health